Donnerstag, 18. Juli 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
INAVO121

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Rekrutierend

NCT-Nummer:
NCT05646862

Studienbeginn:
Juni 2023

Letztes Update:
21.06.2024

Wirkstoff:
Inavolisib, Fulvestrant, Alpelisib

Indikation (Clinical Trials):
Breast Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
Hoffmann-La Roche

Collaborator:
-

Studienleiter

Clinical Trials
Study Director
Hoffmann-La Roche

Kontakt

Reference Study ID Number: WO43919 https://forpatients.roche.com/
Kontakt:
Phone: 888-662-6728 (U.S. Only)
E-Mail: global-roche-genentech-trials@gene.com
» Kontaktdaten anzeigen

Studienlocations
(3 von 198)

Uniklinik RWTH Aachen Klinik für Gynäkologie und Geburtsmedizin
52074 Aachen
GermanyRekrutierend» Google-Maps
Onkologische Schwerpunktpraxis Bielefeld
33604 Bielefeld
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Universitätsklinikum Essen; Zentrum Für Frauenheilkunde
45122 Essen
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
79110 Freiburg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH
49124 Georgsmarienhütte
(Niedersachsen)
GermanyRekrutierend» Google-Maps
Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Gynäkologie und Geburtshilfe
37075 Göttingen
(Niedersachsen)
GermanyRekrutierend» Google-Maps
Mammazentrum Hamburg am Krankenhaus Jerusalem
20357 Hamburg
(Hamburg)
GermanyRekrutierend» Google-Maps
Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie
30625 Hannover
(Niedersachsen)
GermanyRekrutierend» Google-Maps
Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg
69120 Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Brustzentrum Rhein-Ruhr Servicegesellschaft mbH
41061 Mönchengladbach
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Klinik & Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt
80336 München
(Bayern)
GermanyRekrutierend» Google-Maps
St. Vincenz-Krankenhaus GmbH Paderborn Frauen- und Kinderklinik St. Louise
33098 Paderborn
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Studienzentrum Onkologie Ravensburg GbR; Onkologie Ravensburg
88212 Ravensburg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Banner MD Anderson Cancer Center
85234 Gilbert
United StatesRekrutierend» Google-Maps
Marin Cancer Care Inc
94904 Greenbrae
United StatesRekrutierend» Google-Maps
Cancer Blood and Specialty Clinic
90720 Los Alamitos
United StatesRekrutierend» Google-Maps
Los Angeles Cancer Network
90017-4803 Los Angeles
United StatesRekrutierend» Google-Maps
University of California, Irvine Medical Center
92868 Orange
United StatesRekrutierend» Google-Maps
UC Davis Comprehensive Cancer Center
95817 Sacramento
United StatesRekrutierend» Google-Maps
Rocky Mountain Cancer Centers
80220 Denver
United StatesRekrutierend» Google-Maps
Eastern CT Hematology and Oncology Associates
06360-2740 Norwich
United StatesRekrutierend» Google-Maps
Cancer Care Centers of Brevard
32955 Rockledge
United StatesRekrutierend» Google-Maps
Cleveland Clinic Florida
33331 Weston
United StatesRekrutierend» Google-Maps
Emory University Hospital
30322 Atlanta
United StatesRekrutierend» Google-Maps
Winship Cancer Institute at Emory Saint Joseph's Hospital
30342 Atlanta
United StatesRekrutierend» Google-Maps
University of Louisville Hospital; The James Graham Brown Cancer Center
40202 Louisville
United StatesRekrutierend» Google-Maps
Karmanos Cancer Institute.
48201 Detroit
United StatesRekrutierend» Google-Maps
Cancer & Hematology Centers of Western Michigan
49503 Grand Rapids
United StatesRekrutierend» Google-Maps
Minnesota Oncology Hematology
55102 Saint Paul
United StatesRekrutierend» Google-Maps
Novant Health Presbyterain Medical Center
28204 Charlotte
United StatesRekrutierend» Google-Maps
Novant Health Forsyth Medical Center
27103 Winston-Salem
United StatesRekrutierend» Google-Maps
Asante Rogue Regional Medical Center
97504-8332 Medford
United StatesRekrutierend» Google-Maps
Consultants in Medical Oncology and Hematology
19008 Broomall
United StatesZurückgezogen» Google-Maps
Abramson Cancer Center Chester County Hospital; Hematology, Medical Oncology
19380 West Chester
United StatesRekrutierend» Google-Maps
WellSpan Oncology Research
17403 York
United StatesRekrutierend» Google-Maps
Texas Oncology - Dallas Presbyterian Hospital
75231 Dallas
United StatesRekrutierend» Google-Maps
Texas Tech University Health Sciences Center; Department of Internal Medicine
79905 El Paso
United StatesRekrutierend» Google-Maps
Texas Oncology (Flower Mound) - USOR
75028 Flower Mound
United StatesRekrutierend» Google-Maps
The Center for Cancer and Blood Disorders - Fort Worth
76104 Fort Worth
United StatesRekrutierend» Google-Maps
Texas Oncology McKinney
75071 McKinney
United StatesRekrutierend» Google-Maps
Kadlec Clinic Hematology and Oncology
99336-7774 Kennewick
United StatesRekrutierend» Google-Maps
Fundación CENIT para la Investigación en Neurociencias
C1125ABD Buenos Aires
ArgentinaRekrutierend» Google-Maps
Centro Oncologico Korben; Oncology
C1426AGE Ciudad Autonoma Buenos Aires
ArgentinaRekrutierend» Google-Maps
Fundacion CORI para la Investigacion y Prevencion del Cancer
F5300COE La Rioja
ArgentinaAktiv, nicht rekrutierend» Google-Maps
Instituto de Oncología de Rosario
S2000KZE Rosario
ArgentinaRekrutierend» Google-Maps
Hosp Provincial D. Centenarios; Oncology Dept
S2002KDS Rosario
ArgentinaRekrutierend» Google-Maps
CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
J5400DIL San Juan
ArgentinaRekrutierend» Google-Maps
Campbelltown Hospital; Macarthur Cancer Therapy Centre
2560 Campbelltown
AustraliaRekrutierend» Google-Maps
Coffs Harbour Health Campus
2450 Coffs Harbour
AustraliaRekrutierend» Google-Maps
Concord Repatriation General Hospital; Concord Cancer Centre
2139 Concord
AustraliaRekrutierend» Google-Maps
Kinghorn Cancer Centre; St Vincents Hospital
2010 Darlinghurst
AustraliaRekrutierend» Google-Maps
Gosford Hospital; Cancer Care Services
2250 Gosford
AustraliaRekrutierend» Google-Maps
Icon Cancer Care Wesley
4066 Auchenflower
AustraliaRekrutierend» Google-Maps
University of the Sunshine Coast
4556 Sippy Downs
AustraliaRekrutierend» Google-Maps
Sir Charles Gairdner Hospital; Medical Oncology
6009 Perth
AustraliaRekrutierend» Google-Maps
Cliniques Universitaires St-Luc
1200 Bruxelles
BelgiumRekrutierend» Google-Maps
Instituto D?Or de Pesquisa e Ensino ? Hospital DF STAR
70390-140 Brasilia
BrazilRekrutierend» Google-Maps
Hospital do Cancer de Pernambuco - HCP
50040-000 Recife
BrazilRekrutierend» Google-Maps
Instituto D?Or de Pesquisa e Ensino ? Hospital Esperança Recife
Recife
BrazilRekrutierend» Google-Maps
Vencer Oncoclínica - Centro de Pesquisa do Piauí
64049-200 Teresina
BrazilRekrutierend» Google-Maps
Hospital Santa Cruz / Centro de Oncologia D'Or
80420-090 Curitiba
BrazilRekrutierend» Google-Maps
Liga Norte Riograndense Contra O Câncer
59040150 Natal
BrazilRekrutierend» Google-Maps
Santa Casa de Misericordia de Porto Alegre
90020-090 Porto Alegre
BrazilRekrutierend» Google-Maps
Hospital Sao Lucas - PUCRS
90610-000 Porto Alegre
BrazilRekrutierend» Google-Maps
Hospital de Base de Sao Jose do Rio Preto
15090-000 Sao Jose do Rio Preto
BrazilRekrutierend» Google-Maps
Hospital Sírio-Libanês
01308-050 Sao Paulo
BrazilRekrutierend» Google-Maps
Tom Baker Cancer Centre-Calgary
T2N 4N2 Calgary
CanadaRekrutierend» Google-Maps
The Ottawa Hospital - General Campus
K1H 8L6 Ottawa
CanadaRekrutierend» Google-Maps
CIUSSS de l Est de l Ile de Montreal - Hopital Maisonneuve Rosemont
H1T 2M4 Montreal
CanadaRekrutierend» Google-Maps
Centre Hospitalier de l'Universite de Montreal (CHUM)
H2X 0C1 Montreal
CanadaRekrutierend» Google-Maps
Hôpital du Sacré-Coeur de Montreal
H4J 1C5 Montreal
CanadaRekrutierend» Google-Maps
The First Hospital of Jilin University
130021 Changchun City
ChinaRekrutierend» Google-Maps
Sichuan Provincial Cancer Hospital
610041 Chengdu
ChinaRekrutierend» Google-Maps
The First Affiliated Hospital, Chongqing Medical University
400016 Chongqing
ChinaRekrutierend» Google-Maps
Guangdong Provincial People's Hospital; Breast
510180 Guangzhou City
ChinaRekrutierend» Google-Maps
Sun yat-sen University Cancer Center; Internal Medicine of Oncology
510060 Guangzhou
ChinaRekrutierend» Google-Maps
The Second Affiliated Hospital of Zhejiang University School of Medicine
310009 Hangzhou City
ChinaRekrutierend» Google-Maps
Sir Run Run Shaw Hospital Zhejiang University
310016 Hangzhou City
ChinaRekrutierend» Google-Maps
Harbin Medical University Tumor Hospital; Department of Surgery; Pharmacy
150049 Harbin
ChinaRekrutierend» Google-Maps
The Second Affiliated Hospital to Nanchang University
330006 Nanchang
ChinaRekrutierend» Google-Maps
Tianjin Cancer Hospital; Department of Breast Oncology
300000 Tianjin
ChinaRekrutierend» Google-Maps
Union Hospital Tongji Medical College Huazhong University of Science and Technology
430023 Wuhan City
ChinaRekrutierend» Google-Maps
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
710061 Xi'an
ChinaRekrutierend» Google-Maps
Centre Hospitalier de La Cote Basque; Oncologie
64109 Bayonne
FranceRekrutierend» Google-Maps
Centre Leon Berard; Service Oncologie Medicale
69008 Lyon
FranceRekrutierend» Google-Maps
A.O. S. Anna e San Sebastiano; Oncologia
81100 Caserta
ItalyRekrutierend» Google-Maps
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
47014 Meldola
ItalyRekrutierend» Google-Maps
AUSL della Romagna; Dipartimento Oncoematologico - U.O.C. Oncologia
48121 Ravenna
ItalyRekrutierend» Google-Maps
Irccs Centro Di Riferimento Oncologico (CRO)
33081 Aviano
ItalyRekrutierend» Google-Maps
Ospedale San Raffaele; Medical Oncology
20132 Milano
ItalyRekrutierend» Google-Maps
ASL AL - Azienda Sanitaria Locale AL; S.C. Oncologia
15121 Alessandria
ItalyRekrutierend» Google-Maps
AOU Città della Salute e della Scienza di Torino
10126 Torino
ItalyRekrutierend» Google-Maps
Humanitas Centro Catanese Di Oncologia; Oncologia Medica
95045 Misterbianco (CT)
ItalyRekrutierend» Google-Maps
Ospedale S. Giuseppe; Oncologia
50053 Empoli (FI)
ItalyRekrutierend» Google-Maps
Ospedale Santa Chiara; Oncologia Medica
38100 Trento
ItalyRekrutierend» Google-Maps
Kyungpook National University Chilgok Hospital
41404 Daegu
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
National Cancer Center
10408 Goyang-si
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
CHA Bundang Medical Center
13496 Gyeonggi-do
Korea, Republic ofRekrutierend» Google-Maps
Catholic Univ. of Incheon St.Mary's Hospital
21431 Incheon
Korea, Republic ofRekrutierend» Google-Maps
Inha University Hospital
22332 Incheon
Korea, Republic ofRekrutierend» Google-Maps
Korea University Anam Hospital
02841 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Seoul National University Hospital
03080 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Severance Hospital, Yonsei University Health System
03722 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Asan Medical Center
05505 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Gangnam Severance Hospital
06273 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Samsung Medical Center
06351 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Seoul St Mary's Hospital
06591 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde
44280 Guadalajara
MexicoRekrutierend» Google-Maps
Panamerican Clinical Research S.A de C.V.
44670 Guadalajara
MexicoRekrutierend» Google-Maps
RENATI INNOVATION S.A.P.I. de C.V
44680 Guadalajara
MexicoRekrutierend» Google-Maps
Health Pharma Professional Research
03100 Cdmx
MexicoRekrutierend» Google-Maps
COI Centro Oncologico Internacional Santa Fe
01330 Ciudad de México
MexicoAktiv, nicht rekrutierend» Google-Maps
OncoMed; Supportive Care
03100 Ciudad de México
MexicoRekrutierend» Google-Maps
ARKE Estudios Clínicos S.A. de C.V.
06700 Ciudad de México
MexicoRekrutierend» Google-Maps
CENEIT Oncologicos; DENTRO DE CONDOMINIO SAN FRANCISCO
03100 Mexico City
MexicoRekrutierend» Google-Maps
Instituto Nacional de Cancerologia; Oncology
14080 Mexico City
MexicoRekrutierend» Google-Maps
Centrum Onkologii im. Prof. Franciszka ?ukaszczyka; Ambulatorium Chemioterapii
85-796 Bydgoszcz
PolandRekrutierend» Google-Maps
Szpital Morski im.PCK; Oddzial Onkologii Klinicznej, Oddzial Dzienny
81-519 Gdynia
PolandRekrutierend» Google-Maps
Narodowy Instytut Onkologii Odzia? w Gliwicach; Centrum Diagnostyki i Leczenia Chorób Piersi
44-102 Gliwice
PolandRekrutierend» Google-Maps
Przychodnia Lekarska KOMED, Roman Karaszewski
62-500 Konin
PolandAktiv, nicht rekrutierend» Google-Maps
Szpital Wojewódzki im. Miko?aja Kopernika; Oddzia? Dzienny Chemioterapii
75-581 Koszalin
PolandRekrutierend» Google-Maps
Szpital Uniwersytecki w Krakowie; Oddzial Kliniczny Onkologii i Poradnia Onkologiczna
31-501 Kraków
PolandRekrutierend» Google-Maps
MRUKMED Lekarz Beata Madej-Mruk i Partner Spolka Partnerska Oddzial nr 1 w Rzeszowie
35-021 Rzeszow
PolandRekrutierend» Google-Maps
Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Nowotworow Piersi i Chirurgii Rekonstr
02-781 Warszawa
PolandRekrutierend» Google-Maps
Dr. W.M. Szpak Incorporated trading as Rainbow Oncology
4126 Durban
South AfricaRekrutierend» Google-Maps
Medical Oncology Centre of Rosebank; Oncology
2196 Johannesburg
South AfricaRekrutierend» Google-Maps
Richards Bay Oncology Centre
3900 KwaZulu Natal
South AfricaRekrutierend» Google-Maps
ICO L'Hospitalet; Servicio de oncologia medica
08908 L'Hospitalet de Llobregat
SpainRekrutierend» Google-Maps
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
15706 Santiago de Compostela
SpainRekrutierend» Google-Maps
Hospital Universitario de Canarias;servicio de Oncologia
38320 La Laguna
SpainRekrutierend» Google-Maps
Hospital Universitari Vall d'Hebron; Oncology
08035 Barcelona
SpainRekrutierend» Google-Maps
Hospital San Pedro De Alcantara; Servicio de Oncologia
10003 Caceres
SpainRekrutierend» Google-Maps
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
28007 Madrid
SpainRekrutierend» Google-Maps
Hospital Ramon y Cajal; Servicio de Oncologia
28034 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario 12 de Octubre; Servicio de Oncologia
28041 Madrid
SpainRekrutierend» Google-Maps
Hospital Regional Universitario Carlos Haya; Servicio de Oncologia
29011 Malaga
SpainAktiv, nicht rekrutierend» Google-Maps
Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia
30120 Murcia
SpainRekrutierend» Google-Maps
Hospital Universitario Virgen Macarena; Servicio de Oncologia
41009 Sevilla
SpainRekrutierend» Google-Maps
China Medical University Hospital; Surgery
404 Taichung
TaiwanAktiv, nicht rekrutierend» Google-Maps
National Cheng Kung University Hospital
70457 Tainan
TaiwanRekrutierend» Google-Maps
Taipei Veterans General Hospital
11217 Taipei City
TaiwanRekrutierend» Google-Maps
Chang Gung Memorial Hosipital at Linkou
333 Taoyuan City
TaiwanRekrutierend» Google-Maps
Veterans General Hospital - Taichung
40705 Xitun Dist.
TaiwanRekrutierend» Google-Maps
National Taiwan University Hospital; Oncology
10048 Zhongzheng Dist.
TaiwanRekrutierend» Google-Maps
Chulalongkorn Hospital; Medical Oncology
10330 Bangkok
ThailandRekrutierend» Google-Maps
Maharaj Nakorn Chiang Mai Hospital; Department of Medicine
50200 ChiangMai
ThailandRekrutierend» Google-Maps
Songklanagarind Hospital; Department of Oncology
90110 Songkhla
ThailandRekrutierend» Google-Maps
Gulhane Training and Applicaton Hospital
06010 Ankara
TurkeyAktiv, nicht rekrutierend» Google-Maps
Memorial Ankara Hastanesi
06520 Ankara
TurkeyAktiv, nicht rekrutierend» Google-Maps
Dicle University Faculty of Medicine
21280 Diyarbakir
TurkeyRekrutierend» Google-Maps
Trakya University Medical Faculty
22030 Edirne
TurkeyAktiv, nicht rekrutierend» Google-Maps
Medipol Mega Üniversite Hastanesi Göztepe
34214 Istanbul
TurkeyAktiv, nicht rekrutierend» Google-Maps
Marmara Uni Faculty of Medicine; Medical Oncology
34890 Istanbul
TurkeyAktiv, nicht rekrutierend» Google-Maps
Ege Uni Medical Faculty Hospital; Oncology Dept
35100 Izmir
TurkeyRekrutierend» Google-Maps
Katip Celebi University Ataturk Training and Research Hospital; Oncology
35360 Izmir
TurkeyAktiv, nicht rekrutierend» Google-Maps
Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
34722 Kadiköy
TurkeyAktiv, nicht rekrutierend» Google-Maps
Medical Park Seyhan Hospital; Oncology Department
01140 Seyhan
TurkeyRekrutierend» Google-Maps
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
06230 Sihhiye/Ankara
TurkeyAktiv, nicht rekrutierend» Google-Maps
Basingstoke and North Hampshire Hospital
RG24 9NA Basingstoke
United KingdomRekrutierend» Google-Maps
Blackpool Victoria Hospital
FY3 8NR Blackpool
United KingdomAktiv, nicht rekrutierend» Google-Maps
Dumfries and Galloway Royal Infirmary
DG2 8RX Dumfries
United KingdomRekrutierend» Google-Maps
Western General Hospital; Clinical Oncology
EH4 2XU Edinburgh
United KingdomRekrutierend» Google-Maps
Princess Alexandra Hospital
CM20 1QX Harlow
United KingdomAktiv, nicht rekrutierend» Google-Maps
St John's Hospital
EH54 6PP Livingston
United KingdomRekrutierend» Google-Maps
St Bartholomew's Hospital
EC1M 6BQ London
United KingdomRekrutierend» Google-Maps
Maidstone & Tonbridge Wells Hospital; Kent Oncology Center
ME16 9QQ Maidstone
United KingdomRekrutierend» Google-Maps
Mount Vernon & Watford Trust Hospital; Dept. of Clinical Oncology
HA6 2RN Northwood
United KingdomRekrutierend» Google-Maps
Churchill Hospital; Department of Oncology
OX3 7LE Oxford
United KingdomAktiv, nicht rekrutierend» Google-Maps
Royal Preston Hosptial
PR2 9HT Preston
United KingdomRekrutierend» Google-Maps
ROYAL HAMPSHIRE COUNTY HOSPITAL; R&D Office
SO22 5DG Winchester
United KingdomRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate

the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus

fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor

receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast

cancer (mBC), who progressed during or after cyclin dependent kinase 4/6i (CDK4/6i)-based

therapy.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- If pre/perimenopausal women and men treatment with luteinizing hormone-releasing

hormone (LHRH) agonist therapy beginning at least 2 weeks prior to Day 1 of Cycle 1

- Histologically or cytologically confirmed adenocarcinoma of the breast that is locally

advanced or metastatic and is not amenable to surgical or radiation therapy with

curative intent

- Documented HR +/ HER2- tumor according to American Society of Clinical

Oncology/College of American Pathologists (ASCO/CAP) guidelines

- Confirmation of biomarker eligibility: detection of specified mutation(s) of PIK3CA

via specified test

- Disease progression after or during treatment with a combination of CDK4/6i and

endocrine therapy: <= 2 prior lines of systemic therapy in mBC setting; CDK4/6i based

therapy does not need to be the last one received prior study entry; one line of

chemotherapy in mBC setting allowed

- Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors

version 1.1 (RECIST v1.1)

- Participants for whom endocrine-based therapy is recommended and treatment with

cytotoxic chemotherapy is not indicated at time of entry into the study, as per

national or local treatment guidelines

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

- Life expectancy of > 6 months

- Adequate hematologic and organ function prior to initiation of study treatment

Exclusion Criteria:

- Metaplastic breast cancer

- Prior treatment in locally advanced or metastatic setting with any PI3K, AKT, or mTOR

inhibitor or any agent whose mechanism of action is to inhibit the PI3K/-AKT/-mTOR

pathway

- Participant who relapsed with documented evidence of progression > 12 months from

completion of adjuvant CDK4/6i based therapy with no treatment for metastatic disease

- Pregnant, lactating, or breastfeeding, or intending to become pregnant during the

study or at least 60 days after the final dose of study treatment

- Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or

any history of Type 1 diabetes

- Inability or unwillingness to swallow pills

- Malabsorption syndrome or other condition that would interfere with enteral absorption

- Any history of leptomeningeal disease or carcinomatous meningitis

- Known and untreated, or active central nervous system (CNS) metastases. Participants

with a history of treated CNS metastases are eligible if they meet specific certain

criteria

- Known active, systemic infection at study enrollment, or any major episode of

infection requiring treatment with intravenous antibiotics or hospitalization within 7

days prior to Day 1 of Cycle 1

- Any concurrent ocular or intraocular condition that, in the opinion of the

investigator, would require medical or surgical intervention during the study period

to prevent or treat vision loss that might result from that condition

- Active inflammatory or infectious conditions in either eye or history of idiopathic or

autoimmune-associated uveitis in either eye

- Requirement for daily supplemental oxygen

- Symptomatic active lung disease, including pneumonitis

- History of or active inflammatory bowel disease

- Any active bowel inflammation

- Clinically significant and active liver disease, including severe liver impairment,

viral or other hepatitis, current alcohol abuse, or cirrhosis

- Participants with known human immunodeficiency virus infection that meet specific

criteria

- Investigational drug(s) within 4 weeks before randomization or within 5 half-lives of

the investigational drug(s), whichever is longer

- History of other malignancy within 5 years prior to screening, except for cancers with

very low risk of recurrence

- Chronic therapy of >= 10 mg of prednisone per day or an equivalent dose of other

anti-inflammatory corticosteroids or immunosuppressants for a chronic disease

- Allergy or hypersensitivity to components or excipients of the inavolisib,

fulvestrant, or alpelisib formulations

- History of severe cutaneous reactions like Stevens-Johnson Syndrome, Erythema

Multiforme, Toxic Epidermal Necrolysis, or Drug Reaction with Eosinphilia and Systemic

Symptoms

- Active ongoing osteonecrosis of the jaw

Studien-Rationale

Primary outcome:

1. Blinded Independent Central Review (BICR)-Assessed Progression Free Survival (PFS) (Time Frame - From randomization until disease progression or death due to any cause (up to approximately 64 months))



Secondary outcome:

1. Overall survival (OS) (Time Frame - From randomization until death due to any cause (up to approximately 85 months))

2. BICR-Assessed Overall Response Rate (ORR) (Time Frame - Up to approximately 64 months)

3. BICR-Assessed Best Overall Response (BOR) (Time Frame - Up to approximately 64 months)

4. BICR-Assessed Clinical Benefit Rate (CBR) (Time Frame - Up to approximately 64 months)

5. BICR-Assessed Duration of Response (DOR) (Time Frame - From CR or PR until disease progression or death due to any cause (up to approximately 64 months))

6. Time to Confirmed Deterioration (TTCD) in Pain (Time Frame - Day 1 of Cycles 1 and 2 and beyond, 30-day safety follow up visit, post-treatment tumor assessment follow-up with PRO collection and survival follow up visit (up to approximately 85 months). Each cycle is 28 days.)

7. TTCD in Physical Functioning (Time Frame - Day 1 of Cycles 1 and 2 and beyond, 30-day safety follow up visit, post-treatment tumor assessment follow-up with PRO collection and survival follow up visit (up to approximately 85 months). Each cycle is 28 days.)

8. TTCD in Role Functioning (Time Frame - Day 1 of Cycles 1 and 2 and beyond, 30-day safety follow up visit, post-treatment tumor assessment follow-up with PRO collection and survival follow up visit (up to approximately 85 months). Each cycle is 28 days.)

9. TTCD in Global Health Status/Quality of Life (QOL) (Time Frame - Day 1 of Cycles 1 and 2 and beyond, 30-day safety follow up visit, post-treatment tumor assessment follow-up with PRO collection and survival follow up visit (up to approximately 85 months). Each cycle is 28 days.)

10. Percentage of Participants with Adverse Events (Time Frame - Day 1 until 30 days after the final dose of study treatment (up to approximately 85 months))

11. Plasma Concentration of Inavolisib at Specified Timepoints (Time Frame - Day 1 and 15 of Cycle 1, and Day 1 of Cycles 2 and 3. Each cycle is 28 days.)

Studien-Arme

  • Experimental: Inavolisib + Fulvestrant
    Participants will be administered the treatments as outlined in the interventions section.
  • Active Comparator: Alpelisib + Fulvestrant
    Participants will be administered the treatments as outlined in the interventions section.

Geprüfte Regime

  • Inavolisib:
    Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle.
  • Fulvestrant:
    Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.
  • Alpelisib:
    Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.